戻る Agenda
European Relative Effectiveness Assessments
Session Chair(s)
Wim Goettsch, PHD, MSC
Special Advisor HTA
Dutch National Health Care Institute (ZIN), Netherlands
Tomas Salmonson, DrMed, PHD
Critical Path Institute, Netherlands
In the coming years (2016-2020) HTA collaboration in Europe will be intensified in the new EUnetHTA JA3. One of the goals of the EUnetHTA JA3 is facilitate joint assessments of relative effectiveness of pharmaceuticals and to support the use of these joint assessments in national practice. In this panel we will discuss the future of the joint relative effectiveness assessments, their possible use in different types of Member States and the possible alignment of these REAs with the benefit-risk assessments of pharmaceuticals for market authorisation by the EMA.
Speaker(s)
EU Cooperation on Health Technology Assessments
Ioana-Raluca Siska, MD, PHD
European Commission, Belgium
Policy Officer, Health Technology Assessment
Experienced-Based Potentials and Hurdles of European Assessments of Medicines
Anne D'Andon
Haute Autorité De Santé (HAS), France
Head of Medicines Assessment
Country with Developing HTA Methods
Tatyana Benisheva, DrMed, MHS, PHD, RAC
Bulgarian Association for Drug Information , Bulgaria
President